NASDAQ:ATOS

Atossa Therapeutics (ATOS) Stock Forecast, Price & News

$0.83

+0.04 (+5.06%)

(As of 09/22/2023 ET)

Compare

Today's Range: $0.78
▼
$0.84
50-Day Range: $0.74
▼
$1.20
52-Week Range: $0.50
▼
$1.39

Volume: 553,452 shs
Average Volume: 612,960 shs
Market Capitalization: $104.40 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.50

Atossa Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 562.7% Upside
$5.50 Price Target
Short Interest: Bearish
6.52% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -1.05
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.27) to ($0.28) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.65 out of 5 stars

Medical Sector

858th out of 966 stocks

Pharmaceutical Preparations Industry

411th out of 449 stocks

3.5

Analyst's Opinion

Consensus Rating
Atossa Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.50, Atossa Therapeutics has a forecasted upside of 562.7% from its current price of $0.83.
Amount of Analyst Coverage
Atossa Therapeutics has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
6.52% of the outstanding shares of Atossa Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Atossa Therapeutics has a short interest ratio ("days to cover") of 9.6.
Change versus previous month
Short interest in Atossa Therapeutics has recently decreased by 1.80%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Atossa Therapeutics does not currently pay a dividend.
Dividend Growth
Atossa Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ATOS.

1.1

News and Social Media Coverage

News Sentiment
Atossa Therapeutics has a news sentiment score of -1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Atossa Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 7 people have searched for ATOS on MarketBeat in the last 30 days. This is a decrease of -42% compared to the previous 30 days.
MarketBeat Follows
6 people have added Atossa Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Atossa Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 7.80% of the stock of Atossa Therapeutics is held by insiders.
Percentage Held by Institutions
Only 12.74% of the stock of Atossa Therapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Atossa Therapeutics are expected to decrease in the coming year, from ($0.27) to ($0.28) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Atossa Therapeutics is -3.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Atossa Therapeutics is -3.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Atossa Therapeutics has a P/B Ratio of 0.89. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Atossa Therapeutics (NASDAQ:ATOS) Stock

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

ATOS Price History

30 days | 90 days | 365 days | Advanced Chart

ATOS Stock News Headlines

September 18, 2023 | finance.yahoo.com

Atossa to Present at Cantor Fitzgerald Global Healthcare Conference 2023

September 18, 2023 | finance.yahoo.com

Approximately 30% Of Newly Diagnosed Cancers In Women Will Be Breast Cancers - Atossa Therapeutics Has A Promising Drug To Help With Prevention And Treatment

September 23, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.

September 8, 2023 | msn.com

Cantor Fitzgerald Initiates Coverage of Atossa Therapeutics (ATOS) with Overweight Recommendation

September 8, 2023 | msn.com

Atossa stock jumps 16% in wake of Cantor overweight rating

September 8, 2023 | markets.businessinsider.com

Breast Cancer-Focused Atossa Therapeutics Can Possibly Change Treatment Paradigm: Analyst

August 31, 2023 | msn.com

Atossa Therapeutics: Betting Big On Transforming Old Breast Cancer Care

August 31, 2023 | msn.com

Atossa Therapeutics (ATOS) Price Target Increased by 13.51% to 5.36

September 23, 2023 | Legacy Research (Ad)

Reverse ‘money machines’ popping up across America

If you’ve been to a concert venue, stadium, or airport, you’ve almost certainly walked by one without knowing. The experts are calling it a 'Reverse ATM' Why are these machines suddenly appearing out of nowhere? And what does it mean for your money?

August 23, 2023 | proactiveinvestors.com

Atossa Therapeutics is targeting multiple stages of the breast cancer continuum with oral Endoxifen

August 23, 2023 | finance.yahoo.com

Atossa Therapeutics backing Endoxifen in the fight against breast cancer

August 23, 2023 | proactiveinvestors.com

Atossa Therapeutics backing Endoxifen in the fight against...Atossa Therapeutics backing Endoxifen in the fight against breast...

August 15, 2023 | finance.yahoo.com

Q2 2023 Atossa Therapeutics Inc Earnings Call

August 14, 2023 | finance.yahoo.com

Atossa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

July 20, 2023 | msn.com

Atossa gains as Canada greenlights breast cancer trial

July 20, 2023 | finanznachrichten.de

Atossa Therapeutics, Inc.: Atossa Therapeutics Receives Approval from Health Canada to Conduct Phase 2 EVANGELINE Clinical Trial in Canada

July 20, 2023 | proactiveinvestors.com

Atossa Therapeutics gets green light to open enrollment for Phase 2 breast cancer trial in Canada

July 14, 2023 | seekingalpha.com

Atossa Therapeutics regains compliance with Nasdaq's minimum bid price rule

July 11, 2023 | markets.businessinsider.com

Maxim Group Keeps Their Buy Rating on Atossa Therapeutics (ATOS)

July 11, 2023 | proactiveinvestors.com

Maxim upbeat on Atossa Therapeutics after recent updates

July 10, 2023 | finanznachrichten.de

Atossa Therapeutics, Inc.: Atossa Therapeutics Provides Enrollment Update for Ongoing Phase 2 Karisma-Endoxifen Clinical Trial

July 10, 2023 | proactiveinvestors.com

Atossa Therapeutics provides update on Phase 2 breast density trial enrollment

July 8, 2023 | proactiveinvestors.com

Atossa Therapeutics strikes sponsored research deal with Weill Cornell Medicine for triple negative breast cancer

July 6, 2023 | finance.yahoo.com

Atossa Therapeutics Announces Sponsored Research Agreement with Weill Cornell Medicine to Address Treatment Challenges in Triple Negative Breast Cancer

June 29, 2023 | proactiveinvestors.com

Atossa hits 30% enrollment for (Z)-Endoxifen arm of ongoing I-SPY 2 clinical trial

June 28, 2023 | msn.com

Atossa jumps 17% after update on mid-stage trial for breast cancer drug

June 28, 2023 | finance.yahoo.com

Atossa Therapeutics and Quantum Leap Healthcare Provide Enrollment Update for (Z)-Endoxifen Arm of Ongoing I-SPY 2 Clinical Trial

See More Headlines

Receive ATOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atossa Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ATOS Company Calendar

Last Earnings: 8/14/2023
Today: 9/22/2023
Next Earnings (Estimated): 11/06/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ATOS
CUSIP: N/A
CIK: 1488039
Web: atossatherapeutics.com
Phone: (206) 588-0256
Fax: 206-430-1288
Employees: 11
Year Founded: 2009

Price Target and Rating

Average Stock Price Forecast: $5.50
High Stock Price Forecast: $6.00
Low Stock Price Forecast: $5.00
Forecasted Upside/Downside: +562.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.25)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-26,960,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -24.97%
Return on Assets: -24.07%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 30.48
Quick Ratio: 30.48

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.93 per share
Price / Book: 0.89

Miscellaneous

Outstanding Shares: 125,790,000
Free Float: 115,974,000
Market Cap: $104.41 million
Optionable: Not Optionable
Beta: 1.28

Social Links

10 Best Stocks to Own in 2023

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Steven C. Quay FCAP (Age 72)
M.D., Ph.D., Chairman, CEO & Pres
Comp: $1.14M

Mr. Gregory L. Weaver CPA (Age 67)
M.B.A., CFO & Director
Comp: $80k

Ms. Heather Rees
VP of Fin. & Accounting

Ms. Delly Behen P.H.R.
VP of Admin. & HR

Mr. Eric Van Zanten
VP of Investor & PR

Dr. Richard Graydon M.D.
Ph.D., Interim Chief Medical Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ATOS Stock - Frequently Asked Questions

Should I buy or sell Atossa Therapeutics stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Atossa Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATOS shares.
View ATOS analyst ratings or view top-rated stocks.
What is Atossa Therapeutics' stock price forecast for 2023?: 1 brokers have issued 1-year price objectives for Atossa Therapeutics' shares. Their ATOS share price forecasts range from $5.00 to $6.00. On average, they predict the company's stock price to reach $5.50 in the next year. This suggests a possible upside of 562.7% from the stock's current price.
View analysts price targets for ATOS or view top-rated stocks among Wall Street analysts.
How have ATOS shares performed in 2023?: Atossa Therapeutics' stock was trading at $0.5285 on January 1st, 2023. Since then, ATOS stock has increased by 57.0% and is now trading at $0.83.
View the best growth stocks for 2023 here.
When is Atossa Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our ATOS earnings forecast.
How were Atossa Therapeutics' earnings last quarter?: Atossa Therapeutics, Inc. (NASDAQ:ATOS) released its quarterly earnings results on Monday, August, 14th. The company reported ($0.06) earnings per share for the quarter, meeting the consensus estimate of ($0.06).
When did Atossa Therapeutics' stock split?: Atossa Therapeutics shares reverse split before market open on Friday, April 20th 2018. The 1-12 reverse split was announced on Friday, April 20th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, April 19th 2018. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What is Steven C. Quay's approval rating as Atossa Therapeutics' CEO?: 8 employees have rated Atossa Therapeutics Chief Executive Officer Steven C. Quay on Glassdoor.com. Steven C. Quay has an approval rating of 53% among the company's employees. This puts Steven C. Quay in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 29.0% of employees surveyed would recommend working at Atossa Therapeutics to a friend.
What other stocks do shareholders of Atossa Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Atossa Therapeutics investors own include AVEO Pharmaceuticals (AVEO), Alibaba Group (BABA), Heat Biologics (HTBX), Vaxart (VXRT), Biocept (BIOC), MannKind (MNKD), Biopharmx (BPMX), Daré Bioscience (DARE), OPKO Health (OPK) and Nokia Oyj (NOK).
What is Atossa Therapeutics' stock symbol?: Atossa Therapeutics trades on the NASDAQ under the ticker symbol "ATOS."
Who are Atossa Therapeutics' major shareholders?: Atossa Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (2.29%), Geode Capital Management LLC (0.88%), Renaissance Technologies LLC (0.85%), State Street Corp (0.34%), Bank of New York Mellon Corp (0.09%) and Virtu Financial LLC (0.07%).
View institutional ownership trends.
How do I buy shares of Atossa Therapeutics?: Shares of ATOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Atossa Therapeutics' stock price today?: One share of ATOS stock can currently be purchased for approximately $0.83.
How much money does Atossa Therapeutics make?: Atossa Therapeutics (NASDAQ:ATOS) has a market capitalization of $104.41 million. The company earns $-26,960,000.00 in net income (profit) each year or ($0.25) on an earnings per share basis.
How can I contact Atossa Therapeutics?: Atossa Therapeutics' mailing address is 107 SPRING STREET, SEATTLE WA, 98104. The official website for the company is atossatherapeutics.com. The company can be reached via phone at (206) 588-0256, via email at scottg@coreir.com, or via fax at 206-430-1288.

This page (NASDAQ:ATOS) was last updated on 9/23/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial